tiprankstipranks
Advertisement
Advertisement
uniQure upgraded to Outperform from Neutral at Mizuho
PremiumThe FlyuniQure upgraded to Outperform from Neutral at Mizuho
29d ago
uniQure upgraded at Mizuho on potential improvement in regulatory outlook
Premium
The Fly
uniQure upgraded at Mizuho on potential improvement in regulatory outlook
29d ago
uniQure: Regulatory Shift and AMT-130 Outlook Drive Reaffirmed Buy Rating and $70 Target
Premium
Ratings
uniQure: Regulatory Shift and AMT-130 Outlook Drive Reaffirmed Buy Rating and $70 Target
30d ago
Wells gives uniQure second upgrade on Prasad FDA departure
PremiumThe FlyWells gives uniQure second upgrade on Prasad FDA departure
1M ago
uniQure upgraded to Overweight from Equal Weight at Wells Fargo
Premium
The Fly
uniQure upgraded to Overweight from Equal Weight at Wells Fargo
1M ago
uniQure upgraded to Outperform from Sector Perform at RBC Capital
Premium
The Fly
uniQure upgraded to Outperform from Sector Perform at RBC Capital
1M ago
Concerns spurred by FDA push for ‘sham’ brain surgery trial, Bloomberg says
PremiumThe FlyConcerns spurred by FDA push for ‘sham’ brain surgery trial, Bloomberg says
1M ago
ClearPoint Neuro price target lowered to $18 from $28 at B. Riley
Premium
The Fly
ClearPoint Neuro price target lowered to $18 from $28 at B. Riley
1M ago
uniQure Faces Investor Lawsuit Over AMT-130 Trial Disclosures and Stock Drop
Premium
Class Action
uniQure Faces Investor Lawsuit Over AMT-130 Trial Disclosures and Stock Drop
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100